-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Alzheimer's disease is the most common dementia, affecting approximately 50 million people worldwide
prevention
The total global cost of dementia-related diseases is estimated to be approximately US$1,000 billion
Heart blood vessels
AlzeCure Pharma AB (publ) is a Swedish pharmaceutical company that develops drugs for central nervous system diseases.
The MAD Phase I study is AlzeCure's third clinical study, and ACD856 is the main drug candidate in the company's NeuroRestore platform
The MAD Phase I study is AlzeCure's third clinical study, and ACD856 is the main drug candidate in the company's NeuroRestore platform
NeuroRestore is a candidate drug platform for symptom relief for cognitively impaired disease states, such as Alzheimer's disease, sleep apnea, traumatic brain injury and Parkinson's disease
Original source:
Original source:https:// href="https://" target="_blank" rel="noopener">https:// https://